Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep

Vaccine

Volumn 31, Issue 3, 2013, Pages 559-565

  Morrill, John C ^a   Laughlin, Richard C ^b   Lokugamage, Nandadeva ^a   Pugh, Roberta ^b   Sbrana, Elena ^a   Weise, William J ^b   Adams, L Garry ^b   Makino, Shinji ^a   Peters, C J ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

ArMP 12 NSm21 384; Rift Valley fever; RVF MP 12; Sheep

Indexed keywords

NEUTRALIZING ANTIBODY; NSM PROTEIN; RIFT VALLEY FEVER MP 12 VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AUTOPSY; CONTROLLED STUDY; CROSS BREEDING; DRUG EFFICACY; DRUG SAFETY; EWE; FEMALE; FETUS DEATH; GENE DELETION; IMMUNE RESPONSE; IMMUNOGENICITY; LIVESTOCK; MARKER GENE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; RIFT VALLEY FEVER; RIFT VALLEY FEVER BUNYAVIRUS; SEROLOGY; SHEEP; VIRUS DETECTION; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; NEUTRALIZATION TESTS; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SHEEP; UNITED STATES; VACCINES, ATTENUATED; VACCINES, MARKER; VACCINES, SYNTHETIC; VIRAL PLAQUE ASSAY; VIRAL VACCINES;

EID: 84871670827     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.118     Document Type: Article

References (42)

1. Bird B.H., Ksiazek T.G., Nichol S.T., Maclachlan NJ Rift Valley fever virus. J Am Vet Med Assoc 2009, 234:883-893.
2. Ahmed J., Bouloy M., Ergonul O., Fooks A., Paweska J., Chevalier V., et al. International network for capacity building for the control of emerging viral vector-borne zoonotic diseases: ARBO-ZOONET. Euro Surveill 2009, 14.
3. Al-Afaleq A.I., Hussein M.F. The status of Rift Valley fever in animals in Saudi Arabia: a mini review. Vector Borne Zoonotic Dis 2011, 11:1513-1520.
4. Marco Di Luca F.S., Toma L., Romi R. Twenty years of the presence of Aedes albopictus in Italy - from the annoying pest mosquito to the real disease vector. Eur Infect Dis 2011, 2:98-101.
5. Keesing F., Belden L.K., Daszak P., Dobson A., Harvell C.D., Holt R.D., et al. Impacts of biodiversity on the emergence and transmission of infectious diseases. Nature 2010, 468:647-652.
6. Hightower A., Kinkade C., Nguku P.M., Anyangu A., Mutonga D., Omolo J., et al. Relationship of climate, geography, and geology to the incidence of Rift Valley Fever in Kenya during the 2006-2007 outbreak. Am J Trop Med Hyg 2012, 86:373-380.
7. Anyamba A., Linthicum K.J., Small J., Britch S.C., Pak E., de La Rocque S., et al. Prediction, assessment of the Rift Valley fever activity in East and Southern Africa 2006-2008 and possible vector control strategies. Am J Trop Med Hyg 2010, 83:43-51.
8. Christou L. The global burden of bacterial and viral zoonotic infections. Clin Microbiol Infect 2011, 17:326-330.
9. Ikegami T., Makino S. The pathogenesis of Rift Valley fever. Viruses 2011, 3:493-519.
10. Bishop D.H., Calisher C.H., Casals J., Chumakov M.P., Gaidamovich S.Y., Hannoun C., et al. Bunyaviridae. Intervirology 1980, 14:125-143.
11. Walter C.T., Barr J.N. Recent advances in the molecular and cellular biology of bunyaviruses. J Gen Virol 2011, 92:2467-2484.
12. Ikegami T., Won S., Peters C.J., Makino S. Rift Valley fever virus NSs mRNA is transcribed from an incoming anti-viral-sense S RNA segment. J Virol 2005, 79:12106-12111.
13. Bird B.H., Albarino C.G., Nichol S.T. Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 2007, 362:10-15.
14. Won S., Ikegami T., Peters C.J., Makino S. NSm and 78-kilodalton proteins of Rift Valley fever virus are nonessential for viral replication in cell culture. J Virol 2006, 80:8274-8278.
15. Gerrard S.R., Bird B.H., Albarino C.G., Nichol S.T. The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection. Virology 2007, 359:459-465.
16. Won S., Ikegami T., Peters C.J., Makino S. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J Virol 2007, 81:13335-13345.
17. Kakach L.T., Wasmoen T.L., Collett M.S. Rift Valley fever virus M segment: use of recombinant vaccinia viruses to study Phlebovirus gene expression. J Virol 1988, 62:826-833.
18. Kakach L.T., Suzich J.A., Collett M.S. Rift Valley fever virus M segment: phlebovirus expression strategy and protein glycosylation. Virology 1989, 170:505-510.
19. Gerrard S.R., Nichol S.T. Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins. Virology 2007, 357:124-133.
20. Pepin M., Bouloy M., Bird B.H., Kemp A., Paweska J. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res 2010, 41:61.
21. Ikegami T., Narayanan K., Won S., Kamitani W., Peters C.J., Makino S. Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog 2009, 5:e1000287.
22. Muller R., Saluzzo J.F., Lopez N., Dreier T., Turell M., Smith J., et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 1995, 53:405-411.
23. Bouloy M., Janzen C., Vialat P., Khun H., Pavlovic J., Huerre M., et al. Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol 2001, 75:1371-1377.
24. Habjan M., Pichlmair A., Elliott R.M., Overby A.K., Glatter T., Gstaiger M., et al. NSs protein of Rift Valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol 2009, 83:4365-4375.
25. Niklasson B.S., Meadors G.F., Peters C.J. Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters. Acta Pathol Microbiol Immunol Scand C 1984, 92:197-200.
26. Morrill J.C., Jennings G.B., Caplen H., Turell M.J., Johnson A.J., Peters C.J. Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes. Am J Vet Res 1987, 48:1042-1047.
27. Dungu B., Louw I., Lubisi A., Hunter P., von Teichman B., Bouloy M. Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Vaccine 2010, 28:4581-4587.
28. Bettinger G.E., Peters C.J., Pittman P., Morrill J.C., Ranadive M., Kormann R.N., Lokugamage N. Rift Valley fever MP-12 vaccine: a university, government, & industry collaborative development. Rift Valley Fever workshop 2009.
29. Ikegami T., Won S., Peters C.J., Makino S. Rescue of infectious Rift Valley fever virus entirely from cDNA, analysis of virus lacking NSs gene, and expression of a foreign gene. J Virol 2006, 80:2933-2940.
30. Mufti A.M., Wani G.M., Wani N.A., Buchoo B.A., Khan M.Z. Prenatal development of ovine fetus. Small Rumin Res 2000, 38:87-89.
31. Sivachelvan M.N., Ghali Ali M., Chibuzo G.A. Foetal age estimation in sheep and goats. Small Rumin Res 1996, 19:69-76.
32. Tseng C.T., Huang C., Newman P., Wang N., Narayanan K., Watts D.M., et al. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. J Virol 2007, 81:1162-1173.
33. Morrill J.C., Carpenter L., Taylor D., Ramsburg H.H., Quance J., Peters C.J. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine 1991, 9(1):35-41.
34. Meegan J.M., Yedloutschnig R.J., Peleg B.A., Shy J., Peters C.J., Walker J.S., et al. Enzyme-linked immunosorbent assay for detection of antibodies to Rift Valley fever virus in ovine and bovine sera. Am J Vet Res 1987, 48(7):1138-1141.
35. Ksiazek T.G., Jouan A., Meegan J.M., Le Guenno B., Wilson M.L., Peters C.J., et al. Rift Valley fever among domestic animals in the recent West African outbreak. Res Virol 1989, 140(1):67-77.
36. Morrill J.C., Peters C.J. Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in Rhesus monkeys. Vaccine 2003, 21:2994-3002.
37. Morrill J.C., Mebus C.A., Peters C.J. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res 1997, 58(10):1110-1114.
38. Morrill J.C., Mebus C.A., Peters C.J. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res 1997, 58(10):1104-1109.
39. Wilmut I., Sales D.I., Ashworth C.J. Maternal and embryonic factors associated prenatal loss in mammals. J Reprod Fertil 1986, 76:851-864.
40. Givens M.D., Marley M.S.D. Infectious causes of embryonic and fetal mortality. Theriogenology 2008, 70:270-285.
41. Saluzzo J.F., Smith J.F. Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine. Vaccine 1990, 8:369-375.
42. McElroy A.K., Albarino C.G., Nichol S.T. Development of a RVFV ELISA that can distinguish infected from vaccinated animals. Virol. J. 2009, 6:125. 10.1186/1743-422X-6-125.